Interesting: pts. w/KRAS mutations, EGFR wild type (no mut’n), & those w/non-squamous NSCLC do esp well w/ARQ-197 w/Tarceva. #ASCO10

Related posts:

KRAS not as critical; seems to… KRAS not as critical; seems to largely track same as pts w/o EGFR mutn. RT @MaverickN...

Patients with KRAS mutations i… Patients with KRAS mutations in LC appear to do worse overall & benefit les...

BR.19 trial: KRAS mutation sta… BR.19 trial: KRAS mutation status not significantly prognostic, but pts without KRA...

@OBTN Focus on KRAS re: EGFR T… @OBTN Focus on KRAS re: EGFR TKIs for NSCLC presumes RR is the important variable...

Interesting, puzzling, & troub… Interesting, puzzling, & troubling that response rate w/chemo lower in patient...